Скачать или смотреть A Campaign to Defeat Pediatric Brain Tumors: Project Impact Webcast

New Awareness and Funding Campaign Aims to Transform Global Research Efforts and Accelerate Clinical Trials for Pediatric Brain Tumor Patients

WASHINGTON, D.C. and BOSTON, MA (Sept. 12, 2016) – National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, with its partner, the St. Baldrick’s Foundation, the largest private funder of childhood cancer research grants, as well as several world renowned experts in the field of pediatric neuro-oncology, today announced a new awareness and fundraising campaign to support a major translational research and drug discovery program. Goals of the program include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas, including DIPG – the deadliest of pediatric cancers. The campaign, called “Project Impact: A Campaign to Defeat Pediatric Brain Tumors,” was unveiled today at the National Press Club in Washington, D.C. A replay of the live streaming from the event will soon be available at www.braintumor.org/projectimpact.

Featured speakers at the event included:

David Arons, JD, CEO, National Brain Tumor Society,
Roger J. Packer, MD, Senior Vice President of the Center for Neuroscience and Behavioral Medicine and Director of Brain Tumor Institute at Children’s National Health System,
Suzanne J. Baker, PhD, Director of the Brain Tumor Research Division, Co-Leader of the Neurobiology & Brain Tumor Program, and Endowed Chair in Brain Tumor Research at St. Jude Children’s Research Hospital,
Cord Schlobohm, a practicing dentist and father of a child lost to a pediatric brain tumor, and
Danielle Leach, MPA, Senior Director of Advocacy and Government Relations, St. Baldrick’s Foundation, and mother of child who died from a pediatric brain tumor.
“Treatment of pediatric high-grade gliomas has been extremely frustrating with little progress made over the past quarter century,” said Dr. Roger Packer of Children’s National Health System in Washington, D.C., and Scientific Director of the Defeat Pediatric Brain Tumors Research Collaborative. “New molecular insights provide hope that therapies will be dramatically more effective in the very near future. But we need to maintain forward momentum — from discovering the molecular and genetic underpinnings of these tumors, to understanding how these changes drive these tumors, and to ultimately developing effective, biologically precise therapies. This is a major opportunity for the field, patients and their families.”